[Dysfunctional uterine bleeding. Hormonal management with chlormadinone acetate]

Area of Science:

• Gynecology
• Reproductive Endocrinology
• Pharmacology

Background:

• Dysfunctional uterine bleeding (DUB) is a common gynecological condition affecting women of reproductive age.
• Endometrial hyperplasia, a potential precursor to cancer, is frequently associated with DUB.
• Hormonal therapies are a cornerstone in managing DUB, but optimal treatment protocols require further investigation.

Purpose of the Study:

• To evaluate the efficacy of chlormadinone acetate in treating dysfunctional uterine bleeding.
• To assess the effectiveness of a phased hormonal treatment approach (hemostatic, maintenance, consolidation, observation).
• To analyze treatment outcomes across different patient age groups: adolescents, reproductive-aged women, and premenopausal women.

Main Methods:

• A cohort of 138 patients with DUB received hormonal treatment with chlormadinone acetate.
• Dosage was adjusted based on four therapeutic stages: hemostatic, maintenance, consolidation, and observation.
• Patients were stratified into three groups: adolescents (Group I), reproductive life (Group II), and premenopausal (Group III).

Main Results:

• Chlormadinone acetate treatment yielded good results across all four therapeutic stages.
• Histological examination revealed endometrial hyperplasia in 51.9% of patients, with proliferative hyperplasia in 26.6% and secretory hyperplasia in 14.1%.
• Positive outcomes were observed irrespective of the therapeutic stage or patient age group.

Conclusions:

• Chlormadinone acetate is an effective hormonal treatment for dysfunctional uterine bleeding.
• A phased therapeutic approach with chlormadinone acetate demonstrates success in managing DUB across different patient demographics.
• The findings support the use of chlormadinone acetate for DUB, particularly in cases with associated endometrial hyperplasia.